IL-7 germline variant: setting the stage for immune related adverse events.

Treatment with immune checkpoint inhibitors (ICI) is frequently associated with immune related adverse events (irAEs). A new study identified an interleukin 7 (IL-7) allelic variant - rs16906115 - as a major risk factor for development of ICIs-associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high-risk patients to enable better management of ICI therapy and associated irAEs.